172 related articles for article (PubMed ID: 29472057)
1. Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab.
Boudjemaa A; Rousseau-Bussac G; Monnet I
J Thorac Oncol; 2018 Mar; 13(3):e39-e40. PubMed ID: 29472057
[No Abstract] [Full Text] [Related]
2. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
3. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
[No Abstract] [Full Text] [Related]
5. A Cascade of Pembrolizumab-Induced Autoimmune Toxicities with Mixed Responses to Corticosteroids.
Habib R; Gordon J; Zielinski R
J Thorac Oncol; 2018 Jan; 13(1):e8-e9. PubMed ID: 29258672
[No Abstract] [Full Text] [Related]
6. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
Nishino M; Ramaiya NH; Hatabu H; Hodi FS; Armand PF
Br J Haematol; 2018 Mar; 180(5):752-755. PubMed ID: 27861725
[No Abstract] [Full Text] [Related]
7. Facial diplegia after pembrolizumab treatment.
Yost MD; Chou CZ; Botha H; Block MS; Liewluck T
Muscle Nerve; 2017 Sep; 56(3):E20-E21. PubMed ID: 28398689
[No Abstract] [Full Text] [Related]
8. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab.
Otsubo K; Nakatomi K; Furukawa R; Ashida K; Yoneshima Y; Nakanishi Y; Okamoto I
Ann Oncol; 2017 Dec; 28(12):3106-3107. PubMed ID: 28945828
[No Abstract] [Full Text] [Related]
9. Myasthenia gravis exacerbation associated with pembrolizumab.
Zhu J; Li Y
Muscle Nerve; 2016 Sep; 54(3):506-7. PubMed ID: 26802533
[No Abstract] [Full Text] [Related]
10. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
11. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
12. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
13. Pembrolizumab-Induced Microscopic Colitis.
Ahmed M; Francis G
Am J Gastroenterol; 2018 Apr; 113(4):629-630. PubMed ID: 29610496
[No Abstract] [Full Text] [Related]
14. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.
Park ESY; Rabinowits G; Hamnvik OR; Dagi LR
J AAPOS; 2018 Aug; 22(4):310-312. PubMed ID: 29626663
[TBL] [Abstract][Full Text] [Related]
15. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
16. Hidden cost of pembrolizumab therapy.
Gnanapavan S
Mult Scler; 2019 Jun; 25(7):1008-1009. PubMed ID: 30311536
[No Abstract] [Full Text] [Related]
17. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
18. Hyponatremia in a Patient With Cancer.
Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
[No Abstract] [Full Text] [Related]
19. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
[No Abstract] [Full Text] [Related]
20. Pembrolizumab associated hemophagocytic lymphohistiocytosis.
Shah D; Shrestha R; Ramlal R; Hatton J; Saeed H
Ann Oncol; 2017 Jun; 28(6):1403. PubMed ID: 28368439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
